IVF Reads / Choosing an IVF Clinic in India: What Actually Matters
Choosing an IVF Clinic in India: What Actually Matters

Registration with the National ART and Surrogacy Registry is compulsory for every IVF clinic in India under the ART (Regulation) Act 2021, and clinics are classified Level 1 for IUI only or Level 2 for IVF. Quoted success rates are not standardized, and differences between age bands exceed differences between competent clinics.
- Registration with the National ART and Surrogacy Registry is compulsory under the ART (Regulation) Act 2021.
- Clinics are classified Level 1 (IUI only) or Level 2 (IVF and research).
- The Act mandates written patient consent and sets donor screening standards.
- Success rates are not quoted on a standard basis, so clinic figures are rarely comparable.
- Age is the strongest predictor of outcome, and no clinic can change it.
What can you actually verify?
Registration, and not much else. Under the ART (Regulation) Act 2021, every IVF clinic, ART bank and donor program in India must be registered with the National ART and Surrogacy Registry to operate legally.
That is a factual, checkable claim rather than a marketing one, which makes it the most useful thing on this list. Clinics are classified as Level 1, permitted to perform intrauterine insemination only, or Level 2, permitted to perform IVF and research.
- Registration with the National Registry is compulsory.
- Level 1 covers IUI only — confirm the level matches your treatment.
- Donor screening standards are set in law, not by the clinic.
- Written patient consent is mandated.
Asking a clinic for its registration and level is a reasonable question with a definite answer. How it responds to being asked is itself informative.
Verifying any of this is far easier when someone has already assembled it. For Bangalore we have done that: 138 rated fertility clinics, each scored on five weighted signals, with the gaps in the public record stated rather than filled in.
Why success rates are hard to compare
Because there is no standard basis for quoting them. The same underlying results produce very different headline figures depending on the denominator, and nothing requires a clinic to use the less flattering one.
- Per embryo transferred — excludes cycles that never reached transfer.
- Per cycle started — includes cancellations, so it is lower.
- Per patient — counts people rather than attempts.
- Cumulative across cycles — higher than any single-cycle number.
Age matters more than any of it. In HFEA data, birth rate per embryo transferred was 38% for patients aged 18 to 34 and 8% for those aged 43 to 44 — a spread far wider than the difference between competent clinics.
A clinic treating younger patients will report better figures without being better. Our article on reading success rates covers what to ask so that two clinics' numbers mean the same thing.
Related reading
- How to Choose the Right Gynecologist for IVF: 10 Essential Qualities to Look For!
- Searching for a Fertility Center Near Me: How to Find and Choose the Best Clinic for IVF Success
- Understanding IVF: A Comprehensive Guide to In Vitro Fertilization
- In Vivo Fertilization: A Comprehensive Guide for Couples
- IVF Uncovered: Myths, Secrets, and What They Don’t Tell You
- Should You Change Doctors Mid-Treatment?
Comparing clinics?
IVY can explain what the figures you have been given actually measure, and what to ask so they become comparable.
What to ask before committing
Questions with checkable answers, rather than questions that invite reassurance. The useful ones are specific enough that a vague reply is itself a result.
- What is your registration number and level under the ART Act?
- What is your cumulative live birth rate for my age band, over how many patients?
- What is included in the quoted price, and what is not?
- What happens if a cycle is canceled — clinically and financially?
Add two more that people rarely ask. What is reviewed and changed if a first cycle fails? And who will actually perform the retrieval and transfer — the consultant you are meeting, or someone else?
Over a course of treatment, whether a clinic reviews and adapts after a failed cycle matters more to your outcome than the headline percentage that brought you through the door.
What should not decide it
Several things that feel like quality signals carry no information about outcomes, and some are actively misleading.
- Price — a higher fee does not indicate a better clinic.
- Premises — a smart waiting room tells you about capital, not laboratory quality.
- Advertised success rates without a denominator or age band.
- Pressure to decide quickly, which is a reason to slow down.
Add-ons deserve particular skepticism, because they are where margins are highest and evidence is thinnest. ASRM's 2024 position on PGT-A is that its value as routine screening has not been demonstrated, and it remains widely sold as standard — covered in our article on it.
If a clinic offers a menu of add-ons without discussing the evidence for each, that is information about the clinic.
Continuity is worth more than most people weigh it at. Knowing who will perform the retrieval and the transfer, and whether the same clinician reviews the cycle afterwards, tells you something about how the clinic is organized that no brochure will.
Distance and access matter too, and are usually underrated. A stimulation cycle involves repeated early-morning monitoring visits over about two weeks, and a clinic that is difficult to reach turns a hard fortnight into a much harder one.
Finally, be wary of any clinic unwilling to put its answers in writing. Everything on the list above — registration level, what the price includes, what happens on cancellation — is a matter of fact, and a clinic that will only discuss them verbally is choosing to keep them unverifiable.
Not sure what you have been told?
Upload the quote and the figures you have been given. IVY will help you work out what they mean and what is missing.
Keep reading
3 Sources
- The Assisted Reproductive Technology (Regulation) Act, 2021 — legislative overview. PRS Legislative Research
- Fertility treatment 2024: trends and figures. Human Fertilisation and Embryology Authority. HFEA (2024 data)
- The use of preimplantation genetic testing for aneuploidy: a committee opinion (2024). ASRM and SART. Fertility and Sterility 2024;122:421–34
Drafted by the IVFPulse editorial team against guideline bodies and peer-reviewed studies, each cited below. Figures are quoted from the source named beside them and are not IVFPulse's own data. Proposed for clinical review by Dr. Meera Nair, MD, Fertility Specialist — not yet reviewed.
Frequently asked questions
What people ask when choosing where to have treatment.
How do I check if an IVF clinic in India is legitimate?
Ask for its registration with the National ART and Surrogacy Registry, which is compulsory under the ART (Regulation) Act 2021, and confirm its level — Level 1 permits intrauterine insemination only, Level 2 permits IVF and research. This is a factual question with a definite answer, unlike most of what clinics advertise.
Should I choose the clinic with the highest success rate?
Not on the headline figure alone. Rates are quoted on different bases — per embryo transferred, per cycle started, per patient, cumulative — and are rarely comparable. Age matters more: HFEA data show 38% per embryo transferred at 18–34 against 8% at 43–44, a wider spread than between competent clinics.
What questions should I ask an IVF clinic?
Ask for the registration number and level, the cumulative live birth rate for your age band and how many patients it is based on, exactly what the quoted price includes, and what happens clinically and financially if a cycle is canceled. Also ask what gets reviewed and changed if a first cycle fails, and who will perform the retrieval and transfer.
Does a more expensive clinic mean better treatment?
No. Price is not an indicator of outcome, and neither are premises. Add-ons deserve particular scrutiny, since that is where margins are highest and evidence thinnest — ASRM's 2024 position is that the value of PGT-A as routine screening has not been demonstrated, yet it is widely sold as standard.



